MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial-Reference-Cited by-同舟云学术

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

Published:2015-02-05 Issue:9 Volume:21 Page:2057-2064
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Weller Michael,Tabatabai Ghazaleh,Kästner Bärbel,Felsberg Jörg,Steinbach Joachim P.,Wick Antje,Schnell Oliver,Hau Peter,Herrlinger Ulrich,Sabel Michael C.,Wirsching Hans-Georg,Ketter Ralf,Bähr Oliver,Platten Michael,Tonn Jörg C.,Schlegel Uwe,Marosi Christine,Goldbrunner Roland,Stupp Roger,Homicsko Krisztian,Pichler Josef,Nikkhah Guido,Meixensberger Jürgen,Vajkoczy Peter,Kollias Spyros,Hüsing Johannes,Reifenberger Guido,Wick Wolfgang

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 274 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Profile as an Outcome Predictor in Glioblastoma along with MRI Features and Surgical Resection: A Scoping Review;International Journal of Molecular Sciences;2024-09-08

2. Unveiling the role of TAGLN2 in glioblastoma: From proneural-mesenchymal transition to Temozolomide resistance;Cancer Letters;2024-08

3. MGMT promoter methylation is a strong prognostic factor for survival after progression in high-grade gliomas;Chinese Neurosurgical Journal;2024-07-24

4. Current chemotherapy strategies for adults with IDH-wildtype glioblastoma;Frontiers in Oncology;2024-07-19

5. Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme—A Literature Review and Clinical Outcomes;Current Oncology;2024-07-12